DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Extensive Stage Lung Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Biological: Atezolizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Durvalumab
Procedure: Echocardiography Test
Drug: Iadademstat
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan

First Posted Date: 2024-03-01

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT06287775

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States

and more 28 locations

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Phase 1

Recruiting

Conditions: Endometrial Cancer
Cancer of Endometrium
Carcinoma of Endometrium
Endometrial Carcinoma

Interventions: Biological: AdHER2DC vaccine
Biological: Pembrolizumab
Drug: Lenvatinib
Biological: N-803
Device: PATHWAY HER2 (4B5) assay

First Posted Date: 2024-02-12

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06253494

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
Gastrointestinal Cancer
Ovarian Cancer
Metastatic Solid Cancers
Colorectal Cancer
Breast Cancer
Genitourinary Cancer

Interventions: Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: KRAS TCR-Transduced PBL
Biological: GRT-C903/GRT-R904

First Posted Date: 2024-02-12

Last Posted Date: 2025-01-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 210

Registration Number: NCT06253520

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Phase 2

Recruiting

Conditions: Hyperaldosteronism
Hypercortisolism
Cushing s Syndrome

Interventions: Drug: [68Ga]Ga-PentixaFor

First Posted Date: 2024-02-07

Last Posted Date: 2025-05-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 77

Registration Number: NCT06246357

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Phase 2

Recruiting

Conditions: Small Cell Carcinoma of the Bladder
High Grade Neuroendocrine Tumors of the Urinary Tract

Interventions: Drug: Lurbinectedin
Drug: Avelumab

First Posted Date: 2024-01-29

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT06228066

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Not Applicable

Recruiting

Conditions: Healthy Volunteer
Obesity

Interventions: Other: Adjusted Mixed Meal Test
Other: Fixed Mixed Meal Test

First Posted Date: 2024-01-25

Last Posted Date: 2025-04-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 79

Registration Number: NCT06223555

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

Studying TAK-243 in Patients With Advanced Cancer

Phase 1

Recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Indolent Non-Hodgkin Lymphoma
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Drug: UAE Inhibitor TAK-243

First Posted Date: 2024-01-25

Last Posted Date: 2025-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT06223542

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Phase 2

Recruiting

Conditions: Drug Therapy
Cancer Vaccine
Oropharynx
Human Papillomavirus Viruses
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: PRGN-2009

First Posted Date: 2024-01-25

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT06223568

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Recruiting

Conditions: Neurofibromatosis 1
Nerve Sheath Neoplasms

First Posted Date: 2024-01-24

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 225

Registration Number: NCT06222203

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Phase 2

Withdrawn

Conditions: T Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Calaspargase Pegol
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Dexamethasone
Drug: Doxorubicin
Procedure: Echocardiography
Procedure: Lumbar Puncture
Drug: Mercaptopurine
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Biological: Navitoclax
Drug: Pegaspargase
Drug: Nelarabine
Procedure: Positron Emission Tomography
Drug: Thioguanine
Procedure: X-Ray Imaging
Drug: Venetoclax
Drug: Vincristine

First Posted Date: 2024-01-18

Last Posted Date: 2024-05-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT06210750

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy